|Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China|
|Bai Li1; Feng Zhen-ru2; Lu Hai-ying1; Li Wen-gang1; Yu Min1; Xu Xiao-yuan1|
|关键词||hepatitis C, chronic autoantibodies hepatitis, autoimmune|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||ORGAN-SPECIFIC AUTOANTIBODIES ; AUTOIMMUNE HEPATITIS ; VIRUS-INFECTION ; GENERAL-POPULATION ; DISEASE ; THERAPY ; HCV ; INTERFERON ; FREQUENCY ; CHILDREN|
Background Hepatitis C virus (HCV) infection may induce autoimmune response and autoantibodies can be detected in chronic hepatitis C (CHC) patients. However, the reported positive rate of autoantibodies in CHC patients in China varies considerably. In this study, we investigated the prevalence of antinuclear antibodies (ANA) and anti-liver-kidney-microsome type 1 autoantibodies (anti-LKM-1) in a large cohort of CHC patients, and analyzed the factors related to the presence of the autoantibodies.
Methods A total of 360 CHC patients were enrolled in this study. Serum ANA and anti-LKM-1 were detected by indirect immunofluorescence and enzyme-linked immunosorbent assay, respectively. Clinical analysis was performed to disclose the related factors to autoantibody production.
Results The prevalence of ANA and anti-LKM-1 in CHC patients was 12.5% (45/360) and 2.5% (9/360), respectively. Women had a higher prevalence than men (18.9% vs 11.4%, P=0.046). Patients with positive autoantibodies had lower HCV RNA levels (1.2x10(7) copies/L vs 7.2x10(7) Copies/L, P < 0.05). Positive ANA was associated with higher serum globulin (P < 0.05). Stratified analysis showed that there were no significant differences in age, HCV genotype, disease course, clinical stage, prevalence of cirrhosis and interferon therapy between autoantibody-positive and -negative subgroups.
Conclusion Autoantibodies can be induced in the course of CHC, and some CHC patients can even develop autoimmune hepatitis.
|资助机构||National Tenth Five-Year Key Project of Science and Technology of China|
|作者单位||1.Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100034, Peoples R China|
2.Peking Univ, Hosp 1, Dept Clin Lab, Beijing 100034, Peoples R China
|Bai Li,Feng Zhen-ru,Lu Hai-ying,et al. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China[J]. CHINESE MEDICAL JOURNAL,2009,122(1):5-9.|
|APA||Bai Li,Feng Zhen-ru,Lu Hai-ying,Li Wen-gang,Yu Min,&Xu Xiao-yuan.(2009).Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China.CHINESE MEDICAL JOURNAL,122(1),5-9.|
|MLA||Bai Li,et al."Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China".CHINESE MEDICAL JOURNAL 122.1(2009):5-9.|